Evidence map›Paper›PMID 35172559›Full record

ArticleHaematologica2022

The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact.

Jonathan J Pinney, Sara K Blick-Nitko, Andrea M Baran, Derick R Peterson, Hannah E Whitehead, Raquel Izumi, Veerendra Munugalavadla, Karl R Van DerMeid, Paul M Barr, Clive S Zent and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jonathan J PinneyCenter for Vaccine Biology and Immunology; Department of Microbiology and Immunology, University of Rochester, Rochester, NY.
Sara K Blick-NitkoDepartment of Pathology and Laboratory Medicine, University of Rochester, Rochester, NY.
Andrea M BaranDepartment of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY.
Derick R PetersonDepartment of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY.
Hannah E WhiteheadCenter for Vaccine Biology and Immunology; Department of Microbiology and Immunology, University of Rochester, Rochester, NY.
Raquel IzumiAcerta Pharma, a member of the AstraZeneca Group, South San Francisco, CA.
Veerendra MunugalavadlaAstraZeneca, South San Francisco, CA.
Karl R Van DerMeidDepartment of Medicine; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.
Paul M BarrDepartment of Medicine; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.
Clive S ZentDepartment of Medicine; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.
Michael R ElliottCenter for Vaccine Biology and Immunology; Department of Microbiology and Immunology, University of Rochester, Rochester, NY, USA; Center for Cell Clearance and the Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA. mre4n@virginia.edu.
Charles C ChuDepartment of Medicine; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY. charles_chu@urmc.rochester.edu.

Funding

The T32 Predoctoral Training Program in Immunology (PTPI)T32AI007285 · NIAID · UNIVERSITY OF ROCHESTER · PI Scott Andrew Gerber, JACQUES Robert · 1986 to 2026
$7.6M
Immunoregulatory role of CD73 in efferocytosisR01AI114554 · NIAID · UNIVERSITY OF VIRGINIA · PI ELLIOTT, MICHAEL RUSTY · 2015 to 2019
$2.5M
Macrophage regulation of the erythronR01DK119285 · NIDDK · UNIVERSITY OF ROCHESTER · PI ELLIOTT, MICHAEL RUSTY, PALIS, JAMES · 2019 to 2023
$2.3M
Macrophage regulation of the erythronR56DK119285 · NIDDK · UNIVERSITY OF ROCHESTER · PI ELLIOTT, MICHAEL RUSTY, PALIS, JAMES · 2018 to 2018
$100k
NIAID NIH HHS R01 AI114554NIAID NIH HHS T32 AI007285NIDDK NIH HHS R01 DK119285NIDDK NIH HHS R56 DK119285
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellProtein Kinase InhibitorsBenzamidesHumansMacrophagesPhagocytosisPlant LeavesPyrazinesacalabrutinibBenzamidesProtein Kinase InhibitorsPyrazines

Identifiers

PMID35172559
PMCPMC9152969

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.